About this Provider
IA invests in research infrastructure to enable seamless access to expertise and services vital to translate research discoveries into human health impacts. We develop strategic partnerships that are informed by a strong focus on future needs, while working to build a quality workforce – all in support of a vibrant and productive Australian Research and Development ecosystem.
The TIA consortium is enabled by the National Collaborative Research Infrastructure Strategy.
Contact Information
- Translational Research Institute, 37 Kent St, Woolloongabba QLD 4102
TYPE OF CLIENTS
Heading of content section
HOW WE CAN HELP
To enable and accelerate the translation of research discovery along the therapeutic development pipeline by ensuring world class research infrastructure facilities are accessible to the Australian translational research community.
- NIBRT’s bioprocessing courses in a simulated cGMP environment
- Production and characterisation of recombinant proteins in a variety of biological hosts for small molecule drug screening, crystallography, diagnostics, cell culture and vaccines.
- Advanced protein engineering and in vitro display technologies for antibody discovery
- Cell line development and high throughput mammalian clonal selection
- Proven record of development programs through to Phase I cGMP
- Advanced protein bioanalytics – stability studies and characterisation of variants
- Expertise with antibody-drug conjugates and chemical bioconjugation techniques
- Mammalian focus with expertise in viral, microbial and insect systems to 200L scale
- Drug substance to fill and finish
- Full QC testing and release (anticipated TGA inspection Dec 2021).
- Nucleic acids production (e.g. mRNA and DNA) for research development purposes
- Process development and technology transfer
- QC testing
- TGA-licensed GMP manufacture of cell therapy, gene-therapy, cellular immunotherapy (CAR T) and regenerative medicine products for clinical trial and commercial supply
- Non-viral gene transfer and editing technology
- Viral vectors e.g. AAV and lentivirus
- Ex vivo gene therapies for rare diseases
- Cellular immunotherapies (CAR-T)
- Quality management advice and consulting
- TGA- licensed collection and processing of cell therapies
- Screening of compound libraries
- Compounds management and logistics
- High throughput screening
- Assay development
- Optimisation of screening hits and lead compounds
- Synthetic chemistry and IP generation
- Drug metabolism and pharmacokinetics guided lead optimization
- Discovery stage bioanalysis by LC MS/MS
- Preclinical efficacy studies in rodent models of human disease
TIA facilities are directly accessible and in most cases can provide subsidised access to capabilities.
The Pipeline Accelerator scheme was introduced to further reduce the cost of access to a specific capability for therapeutic development projects. It is a competitive scheme that provides up to $50,000 with at least 50% matching funding (co-investment) by applicants.
This scheme runs every six months to provide rapid access to promising early-stage therapeutic development projects.
Services
Short explanation on services (optional) Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua
LOREM IPSUM ET DOLOR AMET
ET
LOREM IPSUM ET DOLOR AMET
DOLOR AMET
Equipment
Short explanation on services (optional) Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua
LOREM IPSUM ET DOLOR AMET
ET
LOREM IPSUM ET DOLOR AMET
DOLOR AMET
People
Short explanation on services (optional) Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua
LOREM IPSUM ET DOLOR AMET
ET
LOREM IPSUM ET DOLOR AMET
DOLOR AMET
Fee based:
Access to TIA-funded capabilities and pricing of projects is guided by the following general principles:
In general, facilities will charge based on a three-tier scheme that is widely adopted by NCRIS capabilities. These tiers are:
- Tier 1 (researchers): Charged to public sector researchers, Tier 1 costings should be based on the actual additional costs to the facility to carry out the project, such as consumables and any additional staff (without overheads) that are not NCRIS-funded. The time of NCRIS-funded staff should not be charged to users.
- Tier 2 (spin-outs and SMEs): Charged to companies spun out of public sector research and SMEs which qualify for the R&D tax cash rebate. The charge would be at the marginal rate to carry out the project plus a loading.
- Tier 3 (industry): Charged to companies who do not qualify as Tier 2. The charge would be at the full commercial rate to carry out the project, i.e. the full cost of salaries plus overheads and consumables.